{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T15:10:05Z","timestamp":1749222605313,"version":"3.41.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.prp.2025.155943","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T14:40:10Z","timestamp":1743345610000},"page":"155943","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Role of genetic factors in imatinib resistance of chronic myeloid leukemia: P53, RB1, ASS1 gene deletions, and chromosome 8 hyperdiploidy"],"prefix":"10.1016","volume":"269","author":[{"given":"Aypara","family":"Hasanova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chingiz","family":"Asadov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aytan","family":"Shirinova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1751-3684","authenticated-orcid":false,"given":"Gunay","family":"Aliyeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zohra","family":"Alimirzoyeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2025.155943_bib1","first-page":"413","article-title":"Case of hypertrophy of the spleen and liver in which death took place from suppuration of the blood","volume":"64","author":"Bennett","year":"1845","journal-title":"Edinb. Med. Surg. J."},{"key":"10.1016\/j.prp.2025.155943_bib2","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0959-8049(00)00454-8","article-title":"Chronic myeloid leukemia: STI 571 magnifies the therapeutic dilemma","volume":"37","author":"Mughal","year":"2001","journal-title":"Eur. J. Cancer"},{"issue":"10","key":"10.1016\/j.prp.2025.155943_bib3","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1038\/leu.2010.174","article-title":"Analysis of genomic breakpoints in p190 and p210 BCR-ABL indicate distinct mechanisms of formation","volume":"24","author":"Score","year":"2010","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.prp.2025.155943_bib4","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.V88.7.2375.bloodjournal8872375","article-title":"The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype","volume":"88","author":"Melo","year":"1996","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.prp.2025.155943_bib5","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1\u2013positive chronic myeloid leukemia","volume":"113","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.prp.2025.155943_bib6","doi-asserted-by":"crossref","first-page":"254","DOI":"10.7326\/0003-4819-122-4-199502150-00003","article-title":"Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy","volume":"122","author":"Kantarjian","year":"1995","journal-title":"Leuk. Serv. Ann. Intern. Med."},{"key":"10.1016\/j.prp.2025.155943_bib7","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","article-title":"Translation of Philadelphia chromosome into therapy for CML","volume":"112","author":"Druker","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.prp.2025.155943_bib8","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat. Med."},{"issue":". 10","key":"10.1016\/j.prp.2025.155943_bib9","doi-asserted-by":"crossref","first-page":"x274","DOI":"10.1093\/annonc\/mdl273","article-title":"Chronic myelogenous leukemia (CML): resistance to tyrosine kinase inhibitors","volume":"17","author":"Hochhaus","year":"2006","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.prp.2025.155943_bib10","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani 1","year":"2013","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.prp.2025.155943_bib11","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase","volume":"27","author":"Hughes","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.prp.2025.155943_bib12","doi-asserted-by":"crossref","first-page":"5118","DOI":"10.1182\/blood-2012-05-356014","article-title":"The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans","volume":"120","author":"Pant","year":"2012","journal-title":"Blood"},{"issue":"3\u20134","key":"10.1016\/j.prp.2025.155943_bib13","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3109\/10428199709051771","article-title":"p53 mutations, methylation and genomic instability in the progression of chronic myeloid leukaemia","volume":"26","author":"Guinn","year":"1997","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.prp.2025.155943_bib14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0165-4608(96)00413-X","article-title":"p53 loss and point mutations are associated with suppression of apoptosis and progression of CML into myeloid blastic crisis","volume":"98","author":"Stuppia","year":"1997","journal-title":"Cancer Genet. Cytogenet."},{"issue":"13","key":"10.1016\/j.prp.2025.155943_bib15","doi-asserted-by":"crossref","first-page":"8371","DOI":"10.1074\/jbc.274.13.8371","article-title":"C-Abl neutralizes the inhibitory effect of Mdm2 on p53","volume":"274","author":"Sionov","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.prp.2025.155943_bib16","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.4161\/cc.3.11.1229","article-title":"BCR\/ ABL recruits p53 tumor suppressor protein to induce drug resistance","volume":"3","author":"Stoklosa","year":"2004","journal-title":"Cell Cycle"},{"issue":"2","key":"10.1016\/j.prp.2025.155943_bib17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1535-6108(03)00020-5","article-title":"BCR\/ABL activates mdm2 mRNA translation via the La antigen","volume":"3","author":"Trotta","year":"2003","journal-title":"Cancer Cell"},{"issue":"19","key":"10.1016\/j.prp.2025.155943_bib18","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1073\/pnas.0602402103","article-title":"Loss of p53 impedes the antileukemic response to BCR-ABL inhibition","volume":"103","author":"Wendel","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.prp.2025.155943_bib19","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.V95.4.1144.004k04_1144_1150","article-title":"Acquired loss of p53 induces blastic transformation in p210(bcr\/abl)-expressing hematopoietic cells: a transgenic study for blast crisis of human CML","volume":"95","author":"Honda","year":"2000","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.prp.2025.155943_bib20","doi-asserted-by":"crossref","first-page":"122","DOI":"10.4161\/cc.23031","article-title":"p53 restoration kills primitive leukemia cells in vivo and increases survival of leukemic mice","volume":"12","author":"Velasco-Hernandez","year":"2013","journal-title":"Cell Cycle"},{"issue":"5","key":"10.1016\/j.prp.2025.155943_bib21","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/leu.2011.7","article-title":"p53stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells","volume":"25","author":"Peterson","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.prp.2025.155943_bib22","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1182\/blood.V78.12.3259.3259","article-title":"Abnormalities of the retinoblastoma gene in the pathogenesis of acute leukemia","volume":"78","author":"Ahuja","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.prp.2025.155943_bib23","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3109\/10428190009059278","article-title":"Alterations of P53 and RB genes and the evolution of the accelerated phase of chronic myeloid leukemia","volume":"38","author":"Beck","year":"2000","journal-title":"Leuk. Lymphoma"},{"issue":"24","key":"10.1016\/j.prp.2025.155943_bib24","first-page":"6141","article-title":"Mechanisms of disease progression and resistance to tyrosine kinase inhibitor therapy in chronic myeloid leukemia: an update","volume":"20","author":"Bavaro","year":"2019"},{"issue":"4","key":"10.1016\/j.prp.2025.155943_bib25","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/sj.leu.2403629","article-title":"Derivative chromosome 9 deletions are a significant feature of childhood Philadelphia chromosome positive acute lymphoblastic leukaemia","volume":"19","author":"Robinson","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.prp.2025.155943_bib26","first-page":"4","article-title":"Wai shan Wong et.al. Application of tri-colour, dual fusion fluorescence in situ hybridization (FISH) system for the characterization of BCR-ABL1 fusion in chronic myelogenous leukaemia (CML) and residual disease monitoring","volume":"9","author":"Siu","year":"2009","journal-title":"BMC Blood Disord."},{"issue":"1","key":"10.1016\/j.prp.2025.155943_bib27","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/ijc.2910180105","article-title":"Nonrandom karyotypic evolution in chronic myeloid leukemia","volume":"18","author":"Mitelman","year":"1976","journal-title":"Int. J. Cancer"},{"issue":"11","key":"10.1016\/j.prp.2025.155943_bib28","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1038\/leu.2015.96","article-title":"Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors","volume":"29","author":"Wang","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.prp.2025.155943_bib29","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.critrevonc.2015.08.020","article-title":"Chronic myeloid leukemia: relevance of cytogenetic and molecular assays","volume":"97","author":"Bennour","year":"2016","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"10.1016\/j.prp.2025.155943_bib30","doi-asserted-by":"crossref","first-page":"1611518","DOI":"10.3389\/pore.2023.1611518","article-title":"Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia","volume":"29","author":"Hasanova","year":"2023","journal-title":"Pathol. Oncol. Res."},{"issue":"6","key":"10.1016\/j.prp.2025.155943_bib31","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer","volume":"7","author":"Melo","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.prp.2025.155943_bib32","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/cncr.21756","article-title":"Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal","volume":"106","author":"Cortes","year":"2006","journal-title":"Cancer"}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825001359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825001359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T14:48:14Z","timestamp":1749221294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033825001359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":32,"alternative-id":["S0344033825001359"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2025.155943","relation":{},"ISSN":["0344-0338"],"issn-type":[{"type":"print","value":"0344-0338"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of genetic factors in imatinib resistance of chronic myeloid leukemia: P53, RB1, ASS1 gene deletions, and chromosome 8 hyperdiploidy","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2025.155943","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"155943"}}